Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06277921
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-08
Brief Title:
Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery
Sponsor:
P Herzen Moscow Oncology Research Institute
Organization:
P Herzen Moscow Oncology Research Institute
Study Overview
Official Title:
90-day Postoperative Morbidity and Mortality After Elective Surgery for Esophageal and Esophagogastric Junction Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESOSTAT
Brief Summary:
Esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure
However esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24 and a mortality rate of 2 to 56 respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation
However esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24 and a mortality rate of 2 to 56 respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation
Detailed Description:
Esophageal and esophago-gastric junction cancer is the seventh most common malignancy and the sixth leading cause of cancer-related mortality worldwide
Surgery remains the primary treatment for esophageal cancer and is one of the most technically challenging interventions in oncological surgery In addition esophagectomy is associated with high risks of postoperative complications with rates varying from clinic to clinic Esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24 and a mortality rate of 2 to 56 respectively
The problem with the available studies of the course of the postoperative period is the significant heterogeneity of research methods which does not allow us to obtain a true picture of the results of surgical treatment of the esophagus and esophagogastric junction cancer in the Russian Federation
To improve the quality of further studies and recommendations on standardization of surgical treatment of esophageal and esophagogastric junction cancer and its morbidity there is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation
Surgery remains the primary treatment for esophageal cancer and is one of the most technically challenging interventions in oncological surgery In addition esophagectomy is associated with high risks of postoperative complications with rates varying from clinic to clinic Esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24 and a mortality rate of 2 to 56 respectively
The problem with the available studies of the course of the postoperative period is the significant heterogeneity of research methods which does not allow us to obtain a true picture of the results of surgical treatment of the esophagus and esophagogastric junction cancer in the Russian Federation
To improve the quality of further studies and recommendations on standardization of surgical treatment of esophageal and esophagogastric junction cancer and its morbidity there is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None